Assertio Holdings, Inc.

NASDAQ:ASRT

Drug Manufacturers - Specialty & Generic

Healthcare
$23.50 +0.04%

+$0.01 today

Market cap
$151.86M
Beta
0.53
P/E (TTM)
-4.2
EPS (TTM)
-$5.55
52W Low $8.61High $23.50

Volume 0.27M

Average 0.33M

ASRT Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Assertio Holdings, Inc.NASDAQ: ASRT

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $725K fell 34.2% year over year, ahead of the -37.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 647.4% from the prior quarter. Over 3 fiscal years it compounded at -22.8% a year.

Context

  • Stock-based compensation amounted to 2.9% of revenue in FY2025, down 1.1 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -34.2% holds above the trailing-twelve-month pace of -37.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$725K+647.4% QoQ
Last fiscal yearDec 2025
$3.45M-31.0% YoY
LTMMar 2026
$3.08M-37.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-34.2%——
1 year-31.0%——
3-year CAGR-22.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
3.45M USD
Year-over-year change
-31.0%
4-year CAGR
-0.6%

Stock-Based Compensation vs competitors

How ASRT compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -37.2% is the 8th highest of 10, against a peer median of -25.3%.
  • Stock-based compensation amounts to 3.0% of revenue for ASRT, versus a peer median of 19.9%.
ASRT Competitors
Stock-Based Compensation for ASRT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$22.45M USD-34.1%+7.7%33.9%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$13.11M USD-11.0%+88.9%—
TCRXTScan Therapeutics, Inc.LTM Mar 2026$10.76M USD-2.0%+37.0%117.7%
VXRTVaxart, Inc.LTM Mar 2026$7.34M USD-25.5%-15.1%2.9%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$5.81M USD-25.3%-16.6%—
LUNGPulmonx CorporationLTM Mar 2026$5.17M USD-77.4%—5.8%
NTRBNutriband Inc.LTM Apr 2026$3.23M USD+3574.0%-47.8%179.0%
ASRTAssertio Holdings, Inc.LTM Mar 2026$3.08M USD-37.2%-22.8%3.0%
INCRInterCure Ltd.LTM Jun 2025₪2.48M ILS+169.6%-35.2%1.0%
XBITXBiotech Inc.LTM Mar 2026$465K USD-90.1%-10.6%—
Peer median (excluding ASRT) —-25.3%-12.8%19.9%

Competitors are the stored peer set for ASRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.28M)109.63M(331.94M)(21.58M)(30.38M)
Depreciation & Amortization29.08M33.4M28.23M25.83M30.01M
Deferred Income Tax0(80.38M)76.2M00
Stock-Based Compensation3.55M7.5M9.16M5.01M3.45M
Change in Working Capital(31.29M)(13.01M)140K5.2M(45.33M)
Accounts Receivables(11K)(996K)48.67M(6.46M)(65.99M)
Inventory4.27M(6.59M)(4.97M)(9.58M)9.68M
Accounts Payables(28.7M)(10.11M)(29.35M)(1.26M)(13.29M)
Other Working Capital(6.85M)4.69M(14.21M)22.5M24.27M
Other Non-Cash Items5.48M21.46M267.82M11.95M14.07M
Operating Cash Flow5.52M78.6M49.6M26.41M(28.18M)
Capital Expenditures(53K)(274K)(628K)00
Acquisitions (Net)(18.47M)(42.4M)1.53M00
Purchases of Investments000(98.61M)(119.2M)
Sales of Investments002.19M49.69M115.38M
Other Investing Activities0000(8.17M)
Investing Cash Flow(18.53M)(42.67M)3.1M(48.91M)(11.99M)
Debt Repayment(9.84M)(750K)(10.5M)00
Common Stock Issued44.86M7.02M000
Common Stock Repurchased(418K)(838K)(7.9M)(350K)0
Dividends Paid00000
Other Financing Activities(5.58M)(13.23M)(25.8M)0(189K)
Financing Cash Flow29.03M(7.79M)(44.2M)(350K)(189K)
Effect of Forex Changes00000
Net Change in Cash16.02M28.13M8.5M(22.85M)(40.36M)
Free Cash Flow5.47M78.32M48.98M26.41M(28.18M)

Assertio Holdings, Inc.

NASDAQ:ASRT

Intrinsic Alpha fair value

Locked

Current Price

$23.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.